[Multicenter study on the litholytic effect of ursodeoxycholic acid. 30 cases].
In the context of a cooperative clinical trial carried out in the Cantons of Basel and Vaud, Switzerland, the litholytic effect of ursodeoxycholic acid (Ursochol) in a daily dose of 9 mg/kg was investigated in 42 patients with radiotransparent gallstones. The litholytic effect was evident in 22 (73%) of the 30 patients followed up for a maximum period of 1 year. Complete dissolution of gallstones was obtained in 40% of cases. In addition, ursodeoxycholic acid significantly reduced (p less than 0,001) the dyspeptic-painful symptoms and the number of biliary colics. Tolerance was excellent. In particular, no cases of diarrhea were observed.
D000328:Adult; D000368:Aged; D002769:Cholelithiasis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003840:Deoxycholic Acid / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography; D014580:Ursodeoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use*
D003840:Deoxycholic Acid; D014580:Ursodeoxycholic Acid
Etude multicentrique sur l'effet litholytique de l'acide ursodésoxycholique. 30 cas.